The role of memantine in the treatment of major depressive disorder: Clinical efficacy and mechanisms of action.

Amidfar, Meysam and Réus, Gislaine Z and Quevedo, Joao and Kim, Yong-Ku (2018) The role of memantine in the treatment of major depressive disorder: Clinical efficacy and mechanisms of action. European journal of pharmacology, 827. pp. 103-111. ISSN 1879-0712

Full text not available from this repository.

Abstract

A developing body of evidence indicates that disturbed glutamate neurotransmission especially through N-methyl-d-aspartate (NMDA) is central to the pathophysiology of major depressive disorder (MDD) and NMDA receptor antagonists have shown therapeutic potential in the MDD treatment. Memantine is an uncompetitive NMDA receptor antagonist, approved for treatment of Alzheimer's disease (AD) that in contrast to other NMDA receptor antagonists at therapeutic doses does not induce highly undesirable side effects. Neuroprotective properties and well tolerability of memantine have been attributed to its unique pharmacological features such as moderate affinity, rapid blocking kinetics and strongly voltage-dependency. In this review we summarized clinical trial evidence of antidepressant effectiveness of memantine and its mechanisms of action. Available data indicate contradictory findings relating to clinical efficacy suggesting further research is necessary in determining as to whether memantine will eventually be an advantageous therapy for MDD. Preclinical data proposed various neurobiological mechanisms underlying antidepressant-like properties of memantine that are responsible for synaptic plasticity and cell survival.

Item Type: Article
Depositing User: Unnamed user with email eprints@fums.ac.ir
Date Deposited: 22 May 2018 05:07
Last Modified: 22 May 2018 05:08
URI: http://eprints.fums.ac.ir/id/eprint/2088

Actions (login required)

View Item View Item